

# Minimally invasive approach to delayed union fractures using allogeneic bone cell therapy

**Audrey Colliou**, Aline Detroux, Guy Heynen, Enrico Bastianelli  
Bone Therapeutics S.A., 37 rue Auguste Piccard, 6041 Gosselies, Belgium

Cell-based therapy offers potential in bone regeneration for the treatment of bone diseases and orthopaedic conditions. Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic cells, administrable via a minimally invasive percutaneous technique; a unique value proposition in the market. The implantation of biologically active osteoblastic cells into the bone fracture site is intended to mimic the natural process of bone formation and create a healthy bone environment by recruiting endothelial and osteoprogenitor cells.

## 1) ALLOB® in Preclinical Studies



### BONE FORMATION MODEL

- Subcutaneous injection over the calvaria of nude mice of ALLOB® cells vs. excipient (control)
- Bone formation evaluated by radiology (Faxitron®) & histomorphometry

➤ **ALLOB® cells induce significant bone formation**

CONTROL


ALLOB®



## 2) ALLOB® in Clinical Studies

### HUMAN ALLOGENEIC OSTEOBLASTIC CELL THERAPY PRODUCT

- ✓ Ready-to-use labelled syringe
- ✓ Single injection
- ✓ Minimally invasive percutaneous technique
- ✓ Short procedure duration



## 3) ALLOB-DU1 TRIAL

Phase I/IIA six-month open-label trial to evaluate the SAFETY and EFFICACY of ALLOB® in the treatment of delayed-union fractures of long bones

### STANDARD-OF-CARE FOR DELAYED UNION FRACTURES:



« Wait and see » approach

Current options for the treatment of an impaired fracture typically involve:

- ✓ Highly invasive surgery
- ✓ Risk of serious complications
- ✓ Painful and months of rehabilitation
- **Large unmet medical need**


### SAFETY AND EFFICACY PRELIMINARY RESULTS

- No safety issues for the first 8 patients
- Positive efficacy results at 6 months:
- ✓ **7 out of 8 patients met primary endpoints**
- ✓ **77% radiological improvement**
- ✓ **68% improvement in pain**

Baseline

Month 3

Month 6



**Potential to become a first-line and early treatment for delayed-union fractures**